Review



c di amp in vivo  (InvivoGen)


Bioz Verified Symbol InvivoGen is a verified supplier
Bioz Manufacturer Symbol InvivoGen manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    InvivoGen c di amp in vivo
    (A) In vitro macrophage assays. RAW 264.7 macrophages were <t>pretreated</t> <t>with</t> <t>c-di-AMP</t> before infection with GFP-expressing B. burgdorferi at low and high MOI. Phagocytosis was assessed by flow cytometry to determine the percentage of GFP-positive cells and GFP MFI. ( B ) Gentamicin protection assay. To assess intracellular spirochete viability, RAW 264.7 macrophages were pretreated with c-di-AMP and subsequently infected with B. burgdorferi for 2.5 hours, followed by treatment with gentamicin (200 µg/mL) to eliminate extracellular bacteria. Following washing and lysis, cell lysates were diluted in BSK-II medium and plated in 96-well plates. Intracellular bacterial viability was assessed by limiting dilution, and data are presented as percentages of B. burgdorferi- positive wells. ( C ) In vivo bacterial clearance. Mice were pretreated intradermally with c-di-AMP before infection with B. burgdorferi (1Χ10 4 spirochetes/ mouse). Spirochetal burden at the site of infection was quantified by qPCR at 5 DPI ( left ), and dissemination was assessed by the frequency of culture-positive tissues at 10 DPI ( right ). Data are presented as mean ± SD of two independent experiments (n = 3–5 mice/ group). Statistical significance was determined using a two-tailed unpaired Student’s t- test for (A) and (B) (*, P < 0.05; **, P < 0.01) and a two-tailed Fisher’s exact test for (C) (***, P < 0.001).
    C Di Amp In Vivo, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 135 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c di amp in vivo/product/InvivoGen
    Average 95 stars, based on 135 article reviews
    c di amp in vivo - by Bioz Stars, 2026-05
    95/100 stars

    Images

    1) Product Images from "Type I interferon signaling promotes early innate control of Borrelia burgdorferi infection"

    Article Title: Type I interferon signaling promotes early innate control of Borrelia burgdorferi infection

    Journal: bioRxiv

    doi: 10.64898/2026.02.13.705697

    (A) In vitro macrophage assays. RAW 264.7 macrophages were pretreated with c-di-AMP before infection with GFP-expressing B. burgdorferi at low and high MOI. Phagocytosis was assessed by flow cytometry to determine the percentage of GFP-positive cells and GFP MFI. ( B ) Gentamicin protection assay. To assess intracellular spirochete viability, RAW 264.7 macrophages were pretreated with c-di-AMP and subsequently infected with B. burgdorferi for 2.5 hours, followed by treatment with gentamicin (200 µg/mL) to eliminate extracellular bacteria. Following washing and lysis, cell lysates were diluted in BSK-II medium and plated in 96-well plates. Intracellular bacterial viability was assessed by limiting dilution, and data are presented as percentages of B. burgdorferi- positive wells. ( C ) In vivo bacterial clearance. Mice were pretreated intradermally with c-di-AMP before infection with B. burgdorferi (1Χ10 4 spirochetes/ mouse). Spirochetal burden at the site of infection was quantified by qPCR at 5 DPI ( left ), and dissemination was assessed by the frequency of culture-positive tissues at 10 DPI ( right ). Data are presented as mean ± SD of two independent experiments (n = 3–5 mice/ group). Statistical significance was determined using a two-tailed unpaired Student’s t- test for (A) and (B) (*, P < 0.05; **, P < 0.01) and a two-tailed Fisher’s exact test for (C) (***, P < 0.001).
    Figure Legend Snippet: (A) In vitro macrophage assays. RAW 264.7 macrophages were pretreated with c-di-AMP before infection with GFP-expressing B. burgdorferi at low and high MOI. Phagocytosis was assessed by flow cytometry to determine the percentage of GFP-positive cells and GFP MFI. ( B ) Gentamicin protection assay. To assess intracellular spirochete viability, RAW 264.7 macrophages were pretreated with c-di-AMP and subsequently infected with B. burgdorferi for 2.5 hours, followed by treatment with gentamicin (200 µg/mL) to eliminate extracellular bacteria. Following washing and lysis, cell lysates were diluted in BSK-II medium and plated in 96-well plates. Intracellular bacterial viability was assessed by limiting dilution, and data are presented as percentages of B. burgdorferi- positive wells. ( C ) In vivo bacterial clearance. Mice were pretreated intradermally with c-di-AMP before infection with B. burgdorferi (1Χ10 4 spirochetes/ mouse). Spirochetal burden at the site of infection was quantified by qPCR at 5 DPI ( left ), and dissemination was assessed by the frequency of culture-positive tissues at 10 DPI ( right ). Data are presented as mean ± SD of two independent experiments (n = 3–5 mice/ group). Statistical significance was determined using a two-tailed unpaired Student’s t- test for (A) and (B) (*, P < 0.05; **, P < 0.01) and a two-tailed Fisher’s exact test for (C) (***, P < 0.001).

    Techniques Used: In Vitro, Infection, Expressing, Flow Cytometry, Bacteria, Lysis, In Vivo, Two Tailed Test



    Similar Products

    c di amp in vivo  (InvivoGen)
    95
    InvivoGen c di amp in vivo
    (A) In vitro macrophage assays. RAW 264.7 macrophages were <t>pretreated</t> <t>with</t> <t>c-di-AMP</t> before infection with GFP-expressing B. burgdorferi at low and high MOI. Phagocytosis was assessed by flow cytometry to determine the percentage of GFP-positive cells and GFP MFI. ( B ) Gentamicin protection assay. To assess intracellular spirochete viability, RAW 264.7 macrophages were pretreated with c-di-AMP and subsequently infected with B. burgdorferi for 2.5 hours, followed by treatment with gentamicin (200 µg/mL) to eliminate extracellular bacteria. Following washing and lysis, cell lysates were diluted in BSK-II medium and plated in 96-well plates. Intracellular bacterial viability was assessed by limiting dilution, and data are presented as percentages of B. burgdorferi- positive wells. ( C ) In vivo bacterial clearance. Mice were pretreated intradermally with c-di-AMP before infection with B. burgdorferi (1Χ10 4 spirochetes/ mouse). Spirochetal burden at the site of infection was quantified by qPCR at 5 DPI ( left ), and dissemination was assessed by the frequency of culture-positive tissues at 10 DPI ( right ). Data are presented as mean ± SD of two independent experiments (n = 3–5 mice/ group). Statistical significance was determined using a two-tailed unpaired Student’s t- test for (A) and (B) (*, P < 0.05; **, P < 0.01) and a two-tailed Fisher’s exact test for (C) (***, P < 0.001).
    C Di Amp In Vivo, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c di amp in vivo/product/InvivoGen
    Average 95 stars, based on 1 article reviews
    c di amp in vivo - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    vivo administration  (InvivoGen)
    95
    InvivoGen vivo administration
    (A) In vitro macrophage assays. RAW 264.7 macrophages were <t>pretreated</t> <t>with</t> <t>c-di-AMP</t> before infection with GFP-expressing B. burgdorferi at low and high MOI. Phagocytosis was assessed by flow cytometry to determine the percentage of GFP-positive cells and GFP MFI. ( B ) Gentamicin protection assay. To assess intracellular spirochete viability, RAW 264.7 macrophages were pretreated with c-di-AMP and subsequently infected with B. burgdorferi for 2.5 hours, followed by treatment with gentamicin (200 µg/mL) to eliminate extracellular bacteria. Following washing and lysis, cell lysates were diluted in BSK-II medium and plated in 96-well plates. Intracellular bacterial viability was assessed by limiting dilution, and data are presented as percentages of B. burgdorferi- positive wells. ( C ) In vivo bacterial clearance. Mice were pretreated intradermally with c-di-AMP before infection with B. burgdorferi (1Χ10 4 spirochetes/ mouse). Spirochetal burden at the site of infection was quantified by qPCR at 5 DPI ( left ), and dissemination was assessed by the frequency of culture-positive tissues at 10 DPI ( right ). Data are presented as mean ± SD of two independent experiments (n = 3–5 mice/ group). Statistical significance was determined using a two-tailed unpaired Student’s t- test for (A) and (B) (*, P < 0.05; **, P < 0.01) and a two-tailed Fisher’s exact test for (C) (***, P < 0.001).
    Vivo Administration, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vivo administration/product/InvivoGen
    Average 95 stars, based on 1 article reviews
    vivo administration - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) In vitro macrophage assays. RAW 264.7 macrophages were pretreated with c-di-AMP before infection with GFP-expressing B. burgdorferi at low and high MOI. Phagocytosis was assessed by flow cytometry to determine the percentage of GFP-positive cells and GFP MFI. ( B ) Gentamicin protection assay. To assess intracellular spirochete viability, RAW 264.7 macrophages were pretreated with c-di-AMP and subsequently infected with B. burgdorferi for 2.5 hours, followed by treatment with gentamicin (200 µg/mL) to eliminate extracellular bacteria. Following washing and lysis, cell lysates were diluted in BSK-II medium and plated in 96-well plates. Intracellular bacterial viability was assessed by limiting dilution, and data are presented as percentages of B. burgdorferi- positive wells. ( C ) In vivo bacterial clearance. Mice were pretreated intradermally with c-di-AMP before infection with B. burgdorferi (1Χ10 4 spirochetes/ mouse). Spirochetal burden at the site of infection was quantified by qPCR at 5 DPI ( left ), and dissemination was assessed by the frequency of culture-positive tissues at 10 DPI ( right ). Data are presented as mean ± SD of two independent experiments (n = 3–5 mice/ group). Statistical significance was determined using a two-tailed unpaired Student’s t- test for (A) and (B) (*, P < 0.05; **, P < 0.01) and a two-tailed Fisher’s exact test for (C) (***, P < 0.001).

    Journal: bioRxiv

    Article Title: Type I interferon signaling promotes early innate control of Borrelia burgdorferi infection

    doi: 10.64898/2026.02.13.705697

    Figure Lengend Snippet: (A) In vitro macrophage assays. RAW 264.7 macrophages were pretreated with c-di-AMP before infection with GFP-expressing B. burgdorferi at low and high MOI. Phagocytosis was assessed by flow cytometry to determine the percentage of GFP-positive cells and GFP MFI. ( B ) Gentamicin protection assay. To assess intracellular spirochete viability, RAW 264.7 macrophages were pretreated with c-di-AMP and subsequently infected with B. burgdorferi for 2.5 hours, followed by treatment with gentamicin (200 µg/mL) to eliminate extracellular bacteria. Following washing and lysis, cell lysates were diluted in BSK-II medium and plated in 96-well plates. Intracellular bacterial viability was assessed by limiting dilution, and data are presented as percentages of B. burgdorferi- positive wells. ( C ) In vivo bacterial clearance. Mice were pretreated intradermally with c-di-AMP before infection with B. burgdorferi (1Χ10 4 spirochetes/ mouse). Spirochetal burden at the site of infection was quantified by qPCR at 5 DPI ( left ), and dissemination was assessed by the frequency of culture-positive tissues at 10 DPI ( right ). Data are presented as mean ± SD of two independent experiments (n = 3–5 mice/ group). Statistical significance was determined using a two-tailed unpaired Student’s t- test for (A) and (B) (*, P < 0.05; **, P < 0.01) and a two-tailed Fisher’s exact test for (C) (***, P < 0.001).

    Article Snippet: To elucidate the effect of c-di-AMP in vivo , mice were pre-treated intradermally with c-di-AMP (50 μg/mouse; InvivoGen, tlrl-nacda) 24-hours before infection with B. burgdorferi (1 × 10 4 spirochetes/mouse).

    Techniques: In Vitro, Infection, Expressing, Flow Cytometry, Bacteria, Lysis, In Vivo, Two Tailed Test